A major US RECOVER trial reports that vagus nerve stimulation can deliver durable improvement for some people with severe, treatment-resistant depression. After 24 months, most patients with active stimulation from the start maintained or improved benefits, an
The most telling moment in this trial didn’t happen in the first weeks—it came after months of living with a disease that had already outlasted nearly everything else.
For the people enrolled in the RECOVER trial. severe depression wasn’t something they could simply “try again” and hope for the best. Many had already failed multiple standard treatments, and many had been sick for decades. The study’s headline result now points to a small implanted device that can keep helping long after the early phase—at least for a portion of patients.
Psychiatry researcher Charles Conway of Washington University in St. Louis said, “We’re seeing people getting better and staying better.”
The treatment is called vagus nerve stimulation (VNS). It involves surgically implanting a small device—similar in size to a pacemaker—under the skin of the chest. A thin wire connects the device to the left vagus nerve in the neck. and the device delivers brief. low-level electrical pulses at regular intervals.
A paper published in the International Journal of Neuropsychopharmacology, authored by Conway and his colleagues, reports long-lasting improvements in some people who had lived with severe depression for years—often for decades.
RECOVER enrolled 493 people in the US. Everyone had at least four failed treatment attempts for their current episode of depression, but many had tried far more. Conway said in 2024 that. “On average. each patient had already tried 13 treatments that failed to help them before they enrolled in the trial. ” and that “They had spent more than half of their lives sick with depression.”.
The trial design also mattered. Participants had VNS devices implanted. but for the first 12 months. only half of the devices were switched on; the other half served as the control group. The 2026 report focuses on the outcomes in 214 patients who had active VNS from the beginning of the trial—specifically whether the improvements reported earlier held up through the second year.
Conway framed the significance in plain terms: “With this kind of chronic, disabling illness, even a partial response to treatment is life-altering,” he said. “And with vagus nerve stimulation we’re seeing that benefit is lasting.”
After 12 months, about 69 percent had a meaningful improvement on at least one measure. Among those people, more than 80 percent maintained or improved their benefits at 24 months across measures of depressive symptoms, quality of life, and daily functioning.
For those who had the strongest response at 12 months—defined as a 50 percent or greater reduction in symptoms—92 percent were typically still showing benefit two years in.
Conway described the outcome as unusually durable for a group like this: “We were shocked that one in five patients was effectively without depressive symptoms at the end of two years. ” he said. “These results are highly atypical. as most studies of markedly treatment-resistant depression have very poor sustainability of benefit. certainly not at two years.”.
The people in this trial weren’t just struggling; many had reached a point where work and daily life had broken down. Conway said the average patient in the trial had lived with depression for 29 years, and three-quarters were unable to work. He also said. “We believe the sample in this trial represents the sickest treatment-resistant depressed patient sample ever studied in a clinical trial.”.
One part of the findings also drew attention: outcomes for people who hadn’t responded in the first year. Roughly one-third of those who showed no meaningful benefit at 12 months went on to improve by 24 months. The implication in the trial results is clear—VNS may take a while to show benefits for some people. even if it isn’t working in the early timeframe.
Not everyone responded, and the trial results do not suggest VNS is a rapid fix. Conway acknowledged that: “Seeing results like that for this complicated illness makes me optimistic about the future of this treatment.”
The study was funded by LivaNova, the company that manufactures the VNS device, and it has a financial interest in the trial’s outcome. The data are intended to inform a coverage decision by the US Centers for Medicare and Medicaid Services, which currently does not cover the therapy.
The US FDA approved VNS for treatment-resistant depression in 2005, though exactly how it works on depression isn’t fully understood. The vagus system includes left and right vagus nerves, and in this therapy, the stimulation is delivered via the left vagus nerve in the neck.
Even so, the investigators’ latest reporting emphasizes a message patients and clinicians often chase in treatment-resistant depression: not just improvement, but staying power. That timeline—from years of illness to two years of observed outcomes—is what makes the trial stand out.
The study has been published in the International Journal of Neuropsychopharmacology. This article was fact-checked by Michael Irving and edited by Peter Dockrill. The outlet notes that if readers spot a mistake, they should let the team know.
vagus nerve stimulation VNS severe depression treatment-resistant depression RECOVER trial International Journal of Neuropsychopharmacology Medicare coverage LivaNova FDA 2005